Cargando…

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models

CONTEXT: Mathematical models may help the analysis of biological systems by providing estimates of otherwise un-measurable quantities such as concentrations and fluxes. The variability in such systems makes it difficult to translate individual characteristics to group behavior. Mixed effects models...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berglund, Martin, Adiels, Martin, Taskinen, Marja-Riitta, Borén, Jan, Wennberg, Bernt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589417/ https://www.ncbi.nlm.nih.gov/pubmed/26422201 http://dx.doi.org/10.1371/journal.pone.0138538

Ejemplares similares

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
por: Adiels, Martin, et al.
Publicado: (2015)

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
por: Björnson, Elias, et al.
Publicado: (2023)

A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model
por: Krengel, Annette, et al.
Publicado: (2013)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
por: Borén, Jan, et al.
Publicado: (2020)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Causes and Consequences of Hypertriglyceridemia
por: Packard, Chris J., et al.
Publicado: (2020)

Dietary Fructose and the Metabolic Syndrome
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects
por: Matikainen, Niina, et al.
Publicado: (2013)

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study
por: Matikainen, Niina, et al.
Publicado: (2018)

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics
por: Björnson, E., et al.
Publicado: (2019)

ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan
por: Hiukka, Anne, et al.
Publicado: (2009)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
por: Taskinen, Marja-Riitta, et al.
Publicado: (2022)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
por: Wilson, Jonathan M., et al.
Publicado: (2020)

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy
por: Yetukuri, Laxman, et al.
Publicado: (2011)

Personal model‐assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD
por: Mardinoglu, Adil, et al.
Publicado: (2017)

Effect of HDL composition and particle size on the resistance of HDL to the oxidation
por: Shuhei, Nakanishi, et al.
Publicado: (2010)

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
por: Vallejo-Vaz, Antonio J, et al.
Publicado: (2020)

ApoE Polymorphism Is Associated With C-Reactive Protein in Low-HDL Family Members and in Normolipidemic Subjects
por: Kahri, Juhani, et al.
Publicado: (2006)

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease
por: Zhang, Cheng, et al.
Publicado: (2020)

Mediating role of atherogenic lipoproteins in the relationship between liver fat and coronary artery calcification
por: Björnson, Elias, et al.
Publicado: (2023)

Improved parameter-estimation with combined PET-MRI kinetic modelling
por: Erlandsson, Kjell, et al.
Publicado: (2015)

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
por: Ginsberg, Henry N, et al.
Publicado: (2021)

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
por: Zheng, Weili, et al.
Publicado: (2022)

Analysis of “On/Off” Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics
por: Lu, J, et al.
Publicado: (2015)

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy
por: Forsblom, Carol, et al.
Publicado: (2010)

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
por: Dallinga-Thie, Geesje M., et al.
Publicado: (2016)

Mice with Chimeric Livers Are an Improved Model for Human Lipoprotein Metabolism
por: Ellis, Ewa C. S., et al.
Publicado: (2013)

Current estimates of T cell kinetics in humans
por: Macallan, Derek C., et al.
Publicado: (2019)

Using mixed-effects modeling to estimate decay kinetics of response to SARS-CoV-2 infection
por: Bottino, Dean, et al.
Publicado: (2021)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain
por: Wimberley, Catriona, et al.
Publicado: (2021)

Correction: Mice with Chimeric Livers Are an Improved Model for Human Lipoprotein Metabolism
Publicado: (2014)

Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2016)

Benchmarking optimization methods for parameter estimation in large kinetic models
por: Villaverde, Alejandro F, et al.
Publicado: (2019)

Non-genetic influences on lipoprotein(a) concentrations
por: Enkhmaa, Byambaa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0tber8a94qoridd1sklvfma7a1